

a means of identifying host cells which may be particularly suited as targets for gene therapy using AAV4-based vector systems. In addition, the identification of this interaction permits the development of new means of purifying AAV4 viral particles.

This work will be published, in part, at Kaludov, N. et al., *J. Virol.* (2001), in press.

Interaction of AAV5 With Sialic Acid

JA Chiorini (NIDCR)

Serial No. E-145-01/0 filed Mar 28, 2001.

This patent application describes the ability of AAV5 (adeno-associated virus, serotype 5) to interact with particular alpha 2,3-linked sialic acid residues on cells. These 2,3-linked sialic acid residues are part of the cell surface receptor(s) for AAV5. The identification of these residues as part of the AAV5 receptor, or receptor complex, provides a means of identifying host cells that may be particularly suited as targets for gene therapy using AAV5-based vector systems. In addition, the identification of this interaction permits the development of new means of purifying AAV5 viral particles.

This work has been published, in part, at Walters, RW et al., *JBC* 276 (No. 23) 20610-16 (June 8, 2001), and Kaludov, N. et al., *J. Virol.* (2001), in press.

Use of Activity Dependent Neurotrophic Factor Derived Peptides for Enhancing Learning and Memory

DE Brenneman and Catherine Spong (NICHD), Ilana Gozes (Tel Aviv University) Serial No/Ref: No.: E-147-96/8 (PCT) filed May 31, 2001 which claims priority to 60/267,805 (E-147-96/6) filed February 8, 2001 and 60/208,944 (E-147-96/5) filed May 31, 2000.

These application(s) disclose the use of ADNF polypeptides, ADNF and ADNF III/ADNP or the ADNF derived peptides SAL (SALLRSIPA) and NAP (NAPVSIPQ) to improve learning and memory. The peptides SAL and NAP are preferred because of their ability to cross the blood-brain barrier and for their ease of synthesis. The peptides, when given alone or in combination, either *in utero* or post-natally, improve performance related to learning and memory. Combinations of NAP and SAL are preferred for prenatal administration. NAP alone is preferred for post-natal administration. The ability to improve learning and memory when given *in utero* makes them attractive as candidates for the development of therapeutics for

prevention or treatment of Down's Syndrome or Fragile X syndrome or other conditions associated with mental retardation. The ability to improve performance related to learning and memory in adults makes them attractive candidates for the development of therapeutics for Alzheimer's disease as well as Down's Syndrome or other conditions associated with mental retardation.

This work has been published, in part, at Gozes I, et al. "Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze" *J Pharmacol Exp Ther*, 293(3):1091-8 (Jun 2000).

Dated: July 6, 2001.

Jack Spiegel,

Director, Division of Technology, Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01-17751 Filed 7-13-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group, Subcommittee A—Cancer Centers.

Date: August 3, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: David E. Maslow, P.h.D., Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard—Room 8117, Bethesda, MD 20892-7405; 301/496-2330.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-17741 Filed 7-13-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel.

Date: August 3, 2001.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Jeanette M. Hosseini, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, Bethesda, MD 20892, (301) 496-5561.

Name of Committee: National Eye Institute Special Emphasis Panel.

Date: August 9, 2001.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD 20814.